Zentalis Pharmaceuticals (ZNTL) Long-Term Investments (2021 - 2024)

Zentalis Pharmaceuticals has reported Long-Term Investments for 4 years, with the latest figure at $349.9 million in Q3 2024.

• For the quarter ending Q3 2024, Long-Term Investments changed N/A year-over-year to $349.9 million; the trailing twelve-month figure through Sep 2024 stood at $349.9 million (changed N/A YoY), and the FY2023 full-year result was $454.9 million, up 2044.35% from the prior year.
• Long-Term Investments for Q3 2024 stood at $349.9 million, down from $389.4 million in the prior quarter.
• The five-year high for Long-Term Investments was $454.9 million in Q4 2023, with the low at $18.9 million in Q1 2023.
• Average Long-Term Investments over 4 years is $168.8 million, with a median of $37.5 million recorded in 2021.
• Year-over-year, Long-Term Investments sank 47.12% in 2023 and soared 2288.19% in 2024.
• Tracing ZNTL's Long-Term Investments over 4 years: stood at $37.5 million in 2021, then tumbled by 43.42% to $21.2 million in 2022, then soared by 2044.35% to $454.9 million in 2023, then retreated by 23.07% to $349.9 million in 2024.
• The last three Long-Term Investments figures came in at $349.9 million (Q3 2024), $389.4 million (Q2 2024), and $451.4 million (Q1 2024), per Business Quant data.

Peer Comparison